Boehringer Ingelheim Launches PED Essentials for Patient Evidence
INGELHEIM, Germany — September 17, 2026 Boehringer Ingelheim announced the launch of PED Essentials, a free online learning hub...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
INGELHEIM, Germany — September 17, 2026 Boehringer Ingelheim announced the launch of PED Essentials, a free online learning hub...
Austin, Texas – August 28, 2026 Natera, Inc. announced a new national partnership with Susan G. Komen to accelerate...
BOSTON, June 22, 2026 Mighty Therapeutics, formerly known as Stealth BioTherapeutics, has officially announced its corporate rebranding, marking a...
INDIANAPOLIS, Sept. 9, 2025, Eli Lilly and Company (NYSE: LLY) has launched a new global initiative, “Brain Health Matters,”...
